Noncoding RNAs (ncRNAs) are emerging as key molecules in human cancer, with the potential to serve as novel markers of disease and to reveal uncharacterized aspects of tumor biology. Here we discover 121 unannotated prostate cancer-associated ncRNA transcripts (PCATs) by ab initio assembly of high-throughput sequencing of polyA + RNA (RNA-Seq) from a cohort of 102 prostate tissues and cells lines. We characterized one ncRNA, PCAT-1, as a prostate-specific regulator of cell proliferation and show that it is a target of the Polycomb Repressive Complex 2 (PRC2). We further found that patterns of PCAT-1 and PRC2 expression stratified patient tissues into molecular subtypes distinguished by expression signatures of PCAT-1-repressed target genes. Taken together, our findings suggest that PCAT-1 is a transcriptional repressor implicated in a subset of prostate cancer patients. These findings establish the utility of RNA-Seq to identify disease-associated ncRNAs that may improve the stratification of cancer subtypes.
A r t i c l e s
Recently, RNA-Seq has provided a method to delineate the entire set of transcriptional aberrations in a disease, including novel transcripts not measured by conventional analyses [1] [2] [3] [4] [5] . To facilitate interpretation of sequence read data, existing computational methods typically process individual samples using either short read gapped alignment followed by ab initio reconstruction 2, 3 or de novo assembly of read sequences followed by sequence alignment 4, 5 . These methods provide a powerful framework to uncover uncharacterized RNA species, including antisense transcripts, short RNAs <250 bp or long intergenic ncRNAs (lincRNAs) >250 bp.
Although still largely unexplored, ncRNAs, particularly lincRNAs, have emerged as a new aspect of biology, with evidence suggesting that they are frequently cell-type specific, contribute important functions to numerous systems 6, 7 and may interact with known cancer genes such as EZH2 (ref. 8) . Indeed, several well-described examples, such as HOTAIR 8, 9 and ANRIL 10, 11 , indicate that ncRNAs may be essential actors in cancer biology, typically facilitating epigenetic gene repression through chromatin-modifying complexes 12, 13 . Moreover, ncRNA expression may confer clinical information about disease outcomes and have utility as diagnostic tests 9, 14 . The characterization of RNA species, their functions and their clinical applicability is therefore a major area of biological and clinical importance.
Here, we describe a comprehensive analysis of lincRNAs in 102 prostate cancer tissue samples and cell lines by RNA-Seq. We apply ab initio computational approaches to delineate the annotated and unannotated transcripts in this disease, and we find 121 ncRNAs, termed PCATs, whose expression patterns distinguish benign, localized cancer and metastatic cancer samples. Notably, we discover PCAT-1, a previously undescribed prostate cancer ncRNA that demonstrates either repression by PRC2 or an active role in promoting cell proliferation through transcriptional regulation of target genes. To our knowledge, our findings describe the first comprehensive study of lincRNAs in prostate cancer, provide a computational framework for large-scale RNA-Seq analyses and describe PCAT-1 as a prostate cancer ncRNA functionally implicated in disease progression.
RESULTS

RNA-Seq analysis of the prostate cancer transcriptome
Over two decades of research have generated a genetic model of prostate cancer based on numerous neoplastic events, such as loss of the PTEN 15 tumor suppressor gene and gain of oncogenic ETS family transcription factor gene fusions [16] [17] [18] in large subsets of prostate cancer patients. As some patients lack these genetic aberrations, we hypothesized that prostate cancer similarly harbored diseaseassociated ncRNAs that characterized specific molecular subtypes.
To pursue this hypothesis, we applied transcriptome sequencing on a cohort of 102 prostate tissues and cell lines-20 benign adjacent prostates (benign), 47 localized prostate cancers (PCA), 14 metastatic transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincrNA implicated in disease progression tumors and 21 prostate cell lines. From a total of 1.723 billion sequence fragments from 201 lanes of sequencing (108 paired-end and 93 single reads on the Illumina Genome Analyzer and Genome Analyzer II), we performed short-read gapped alignment 19 and recovered 1.41 billion mapped reads, with a median of 14.7 million mapped reads per sample ( Supplementary Table 1 ). We used the Cufflinks ab initio assembly approach 3 to produce, for each sample, the most probable set of putative transcripts that served as the RNA templates for the sequence fragments in that sample ( Fig. 1a and Supplementary Figs. 1 and 2) .
As expected from a large tumor tissue cohort, individual transcript assemblies may have sources of noise, such as artifacts of the sequence alignment process, unspliced intronic pre-mRNA and genomic DNA contamination. To exclude these from our analyses, we trained a decision tree to classify transcripts as expressed versus background on the basis of transcript length, number of exons, recurrence in multiple samples and other structural characteristics ( Fig. 1b, left, and Supplementary Methods). The classifier demonstrated a sensitivity of 70.8% and specificity of 88.3% when trained using transcripts that overlapped genes in the AceView database 20 , including 11.7% of unannotated transcripts that were classified as expressed ( Fig. 1b  right) . We then clustered the expressed transcripts into a consensus transcriptome and applied additional heuristic filters to further refine the assembly (Supplementary Methods). The final ab initio transcriptome assembly yielded 35,415 distinct transcriptional loci (Supplementary Table 2 and Supplementary Methods).
Discovery of prostate cancer noncoding RNAs
We compared the assembled prostate cancer transcriptome to the UCSC, Ensembl, RefSeq, Vega and ENCODE gene databases to identify and categorize transcripts (Fig. 1c) . The majority of the transcripts (77.3%) corresponded to annotated protein coding genes (72.1%) and noncoding RNAs (5.2%), but a substantial percentage (19.8%) lacked any overlap and were designated unannotated ( Fig. 2a) . These included partially intronic antisense (2.44%), totally intronic (12.1%) and intergenic transcripts (5.25%), consistent with previous reports of unannotated transcription [21] [22] [23] . Because of the added complexity of characterizing antisense or partially intronic transcripts without strand-specific RNA-Seq libraries, we focused on totally intronic and intergenic transcripts.
Global characterization of unannotated intronic and intergenic transcripts demonstrated that they were more highly expressed ( Fig. 2b) , had greater overlap with expressed sequence tags (ESTs) (Supplementary Fig. 3 ) and displayed a clear but subtle increase in conservation over randomly permuted controls (intergenic transcripts P = 2.7 × 10 −4 ± 0.0002 for 0.4 < ω < 0.8; intronic transcripts P = 2.6 × 10 −5 ± 0.0017 for 0 < ω < 0.4, Fisher's exact test, Fig. 2c ). By contrast, unannotated transcripts scored lower than protein-coding genes for these metrics, which corroborates data in previous reports 2, 24 . Notably, a small subset of unannotated intronic transcripts showed a profound degree of conservation ( Fig. 2c, inset) . Finally, analysis of coding potential revealed that only 5 of 6,144 transcripts harbored a highquality open reading frame (ORF), indicating that the vast majority of these transcripts represent ncRNAs ( Supplementary Fig. 4 Figure 1 Analysis of transcriptome data for the detection of unannotated transcripts. (a) Schematic overview of the methodology employed in this study. (b) Graphical representation of the bioinformatics filters used to merge individual transcriptome libraries into a single consensus transcriptome. The merged consensus transcriptome was generated by compiling all individual transcriptome libraries and using individual decision tree classifiers for each chromosome to define high-confidence 'expressed' transcripts and low-confidence 'background' transcripts, which were discarded. The example decision tree on the left was trained on transcripts on chromosome 1. The graphics on the right illustrate the application of the informatics filtration pipeline to sample assembled transcripts. (c) After informatic processing and filtration of the sequencing data, transcripts were categorized to identify unannotated ncRNAs. Transcribed pseudogenes were isolated, and the remaining transcripts were categorized based on overlap with an aggregated set of known gene annotations into annotated protein coding, noncoding and unannotated. Both annotated and unannotated ncRNA transcripts were then separated into intronic, intergenic and antisense categories based on their relationship to protein-coding genes.
A r t i c l e s
To determine whether our unannotated transcripts were supported by histone modifications defining active transcriptional units, we used published prostate cancer chromatin immunoprecipitation (ChIP)-Seq data for two prostate cell lines 25 , VCaP and LNCaP (Supplementary Table 3 ). After filtering our data set for transcribed repetitive elements known to display alternative patterns of histone modifications 26 , we observed a strong enrichment for histone modifications characterizing transcriptional start sites (TSSs) and active transcription, including H3K4me2, H3K4me3, acetyl-H3 and RNA polymerase II ( Fig. 2d-g) , but not H3K4me1, which characterizes enhancer regions 27 (Supplementary Figs. 5 and 6) . Notably, intergenic ncRNAs showed greater enrichment compared to intronic ncRNAs in these analyses ( Fig. 2d-g) .
To elucidate global changes in transcript abundance in prostate cancer, we analyzed differential expression for all transcripts. We found 836 genes differentially expressed between benign samples and localized tumors (false-discovery rate (FDR) < 0.01), with annotated protein-coding and ncRNA genes constituting 82.8% and 7.4% of differentially expressed genes, respectively, including known prostate cancer biomarkers such AMACR 28 , HPN 29 and PCA3 (ref. 14) ( Fig. 2h, Supplementary Fig. 2 and Supplementary Table 4 ). Finally, 9.8% of differentially expressed genes corresponded to unannotated ncRNAs, including 3.2% within gene introns and 6.6% in intergenic regions.
Characterization of PCATs
As ncRNAs may contribute to human disease 6-9 , we identified aberrantly expressed uncharacterized ncRNAs in prostate cancer. We found a total of 1,859 unannotated lincRNAs throughout the human genome. Overall, these intergenic RNAs resided approximately halfway between two protein coding genes ( Supplementary Fig. 7) , and over one-third (34.1%) were ≥10 kb from the nearest protein-coding gene, which is consistent with previous reports 30 and supports the independence of intergenic ncRNAs genes. For example, visualizing the Chr15q arm using the Circos program (http://circos.ca/) illustrated genomic positions of 89 unannotated intergenic transcripts, including one differentially expressed gene centromeric to TLE3 (Supplementary Fig. 8) .
A focused analysis of the 1,859 unannotated intergenic RNAs yielded 106 that were differentially expressed in localized tumors (FDR < 0.05, Fig. 3a) . A cancer outlier expression analysis (Supplementary Methods) similarly nominated numerous unannotated ncRNA outliers ( Fig. 3b ) as well as known prostate cancer outliers, such as ERG 18 , ETV1 (refs. 17, 18) , SPINK1 (ref. 31 ) and CRISP3 (ref. 32 ). Merging these results produced a set of 121 unannotated transcripts that accurately discriminated benign, localized tumor and metastatic prostate samples by unsupervised clustering (Fig. 3a) . Indeed, clustering analyses using unannotated ncRNA outliers also suggested disease subtypes ( Supplementary Fig. 9 ). These 121 unannotated transcripts were ranked and named as PCATs according to their fold-change in localized tumor versus benign tissue ( Supplementary  Tables 5-7) .
Validation of novel ncRNAs
To gain confidence in our transcript nominations, we validated multiple unannotated transcripts in vitro by reverse transcription PCR (RT-PCR) and quantitative real-time PCR (qPCR) ( Supplementary  Fig. 10 ). qPCR for four transcripts (PCAT-114, PCAT-14, PCAT-43 and PCAT-1) on two independent cohorts of prostate tissues confirmed predicted cancer-specific expression patterns ( Fig. 3c-f and Supplementary Fig. 11) . Notably, all four are prostate-specific, with minimal expression seen by qPCR in breast (n = 14) or lung cancer (n = 16) cell lines or in 19 normal tissue types ( Supplementary Table 8 ). This is further supported by expression analysis of these transcripts in our RNA-Seq compendium of 13 tumor types, representing 325 samples ( Supplementary  Fig. 12 ). This tissue specificity was not necessarily due to regulation by androgen receptor signaling, as only PCAT-14 expression was induced when androgen responsive VCaP and LNCaP cells were treated with the synthetic androgen R1881, consistent with previous data from this locus 17 (Supplementary Fig. 13 ). PCAT-1 and PCAT-14 also showed cancer-specific upregulation when tested on a panel of matched tumor-normal pair samples (Supplementary Fig. 14) .
Of note, PCAT-114, which ranks as the fifth best outlier, just ahead of ERG ( Fig. 3b and Supplementary Table 7) , appears as part of a large, >500 kb locus of expression in a gene desert in Chr2q31. We termed this region 'second chromosome locus associated with prostate-1' (SChLAP1) (Supplementary Fig. 15 ). Careful analysis of the SChLAP1 locus revealed both discrete transcripts and intronic transcription, highlighting this region as an intriguing aspect of the prostate cancer transcriptome.
PCAT-1, an unannotated prostate cancer lincRNA
To explore several transcripts more closely, we carried out 5′ and 3′ rapid amplification of cDNA ends (RACE) for PCAT-1 and PCAT-14.
Interestingly, the PCAT-14 locus contained components of viral ORFs from the HERV-K endogenous retrovirus family ( Supplementary  Fig. 16 ), whereas PCAT-1 incorporates portions of a mariner family transposase 33, 34 , an Alu and a viral long terminal repeat promoter region ( Fig. 4a and Supplementary Fig. 17) . Whereas PCAT-14 was upregulated in localized prostate cancer but largely absent in metastases ( Fig. 3c) , PCAT-1 was strikingly upregulated in a subset of metastatic and high-grade localized (Gleason score ≥7) cancers ( Fig. 3f  and Supplementary Fig. 11 ). Because of this notable profile, we hypothesized that PCAT-1 may have coordinated expression with the oncoprotein EZH2, a core PRC2 protein that is upregulated in solid tumors and contributes to a metastatic phenotype 35, 36 . Surprisingly, we found that PCAT-1 and EZH2 expression were nearly mutually exclusive (Fig. 4b) , with only one patient showing outlier expression of both. This suggests that outlier PCAT-1 and EZH2 expression may define two subsets of high-grade disease.
PCAT-1 is located in the chromosome 8q24 gene desert ~725 kb upstream of the c-MYC oncogene. To confirm that PCAT-1 is a noncoding gene, we cloned the full-length PCAT-1 transcript and performed in vitro translational assays, which were negative as expected (Supplementary Fig. 18 ). Next, because Chr8q24 is known to harbor prostate cancer-associated single nucleotide polymorphisms (SNPs) and to exhibit frequent chromosomal amplification [37] [38] [39] [40] [41] [42] , we evaluated whether the relationship between EZH2 and PCAT-1 was specific or generalized. To address this, we measured expression levels of c-MYC and NCOA2, two proposed targets of Chr8q amplification 39, 42 , by qPCR. Neither c-MYC nor NCOA2 levels showed striking expression relationships to PCAT-1, EZH2 or each other (Supplementary Fig. 19) . Likewise, PCAT-1 outlier expression was not dependent on Chr8q24 amplification, as highly expressing localized tumors often did not have 8q24 amplification and high copy number gain of 8q24 was not sufficient to upregulate PCAT-1 (Supplementary Figs. 20 and 21) .
PCAT-1 function and regulation
Despite reports showing that upregulation of the ncRNA HOTAIR participates in PRC2 function in breast cancer 9 , we do not observe strong expression of this ncRNA in prostate (Supplementary Fig. 22 ), suggesting that other ncRNAs may be important in this cancer. To determine the mechanism for the expression profiles of PCAT-1 and A r t i c l e s EZH2, we inhibited EZH2 activity in VCaP cells, which express lowto-moderate levels of PCAT-1. Knockdown of EZH2 by short hairpin (sh)RNA or pharmacologic inhibition of EZH2 with the inhibitor 3-deazaneplanocin A (DZNep) caused a dramatic upregulation in PCAT-1 expression levels (Fig. 4c,d) , as did treatment of VCaP cells with the demethylating agent 5′deoxyazacytidine, the histone deacetylase inhibitor SAHA or both (Fig. 4e) . ChIP assays also demonstrated that SUZ12, a core PRC2 protein, directly binds the PCAT-1 promoter ~1 kb upstream of the TSS (Fig. 4f) . Notably, RNA immunoprecipitation similarly showed binding of PCAT-1 to SUZ12 protein in VCaP cells (Supplementary Fig. 23a ). RNA immunoprecipitation assays followed by RNase A, RNase H or DNase I treatment either abolished, partially preserved or totally preserved this interaction, respectively (Supplementary Fig. 23b ). This suggests that PCAT-1 exists primarily as a single-stranded RNA and secondarily as a RNA/DNA hybrid. To explore the functional role of PCAT-1 in prostate cancer, we stably overexpressed full-length PCAT-1 or controls in RWPE benign immortalized prostate cells. We observed a modest but consistent increase in cell proliferation when PCAT-1 was overexpressed at physiological levels ( Fig. 5a and Supplementary Fig. 24 ). Next, we designed short interfering (si)RNA oligos to PCAT-1 and performed knockdown experiments in LNCaP cells, which express higher levels of PCAT-1 without PRC2-mediated repression (Supplementary Fig. 25 ). Supporting our overexpression data, knockdown of PCAT-1 with three independent siRNA oligos resulted in a 25-50% decrease in cell proliferation in LNCaP cells (Fig. 5b) , but not in control DU145 cells lacking PCAT-1 expression ( Supplementary Fig. 26 ) or VCaP cells, in which PCAT-1 is expressed but repressed by PRC2 (Supplementary Fig. 27) .
Gene expression profiling of LNCaP knockdown samples on cDNA microarrays indicated that PCAT-1 modulates the transcriptional regulation of 370 genes (255 upregulated, 115 downregulated; FDR ≤ 0.01) ( Supplementary Fig. 28 and Supplementary Table 9 ). Gene ontology analysis of the upregulated genes showed preferential enrichment for gene set concepts such as mitosis and cell cycle, whereas the downregulated genes had no concepts showing statistical significance ( Fig. 5c and Supplementary Table 10) . These results suggest that the function of PCAT-1 is predominantly repressive in nature, similar to other lincRNAs. We next validated expression changes in three key PCAT-1 target genes (BRCA2, CENPE and CENPF) whose expression is upregulated upon PCAT-1 knockdown (Fig. 6a) in LNCaP and VCaP cells, the latter of which appear less sensitive to PCAT-1 knockdown likely due to lower overall expression levels of this transcript.
PCAT-1 signatures in prostate cancer
Because of the regulation of PCAT-1 by PRC2 in VCaP cells, we hypothesized that knockdown of EZH2 would also downregulate PCAT-1 targets as a secondary phenomenon owing to the subsequent upregulation of PCAT-1. Simultaneous knockdown of PCAT-1 and EZH2 would thus abrogate expression changes in PCAT-1 target genes. Carrying out this experiment in VCaP cells demonstrated that PCAT-1 target genes were indeed downregulated by EZH2 knockdown, and that this change was either partially or completely reversed using siRNA oligos to PCAT-1 (Fig. 6a) , lending support to the role of PCAT-1 as a transcriptional repressor. Taken together, these results suggest that PCAT-1 biology may exhibit two distinct modalities: one in which PRC2 represses PCAT-1 and a second in which active PCAT-1 promotes cell proliferation. PCAT-1 and PRC2 may therefore characterize distinct subsets of prostate cancer.
To examine these findings, we used qPCR to measure expression of BRCA2, CENPE and CENPF in our cohort of tissue samples. Consistent with our model, we found that samples expressing PCAT-1 tended to have low expression of PCAT-1 target genes (Fig. 6b) .
Moreover, comparing EZH2-outlier and PCAT-1-outlier patients (Fig. 4b) , we found that two distinct phenotypes emerged. Individuals with high EZH2 tended to have high levels of PCAT-1 target genes, and those with high expression of PCAT-1 itself displayed the opposite expression pattern of target genes (Fig. 6c) . Network analysis of the top 20 upregulated genes after PCAT-1 knockdown with the HefaLMP tool 43 further suggested that these genes form a coordinated network (Fig. 6d) , corroborating our previous observations. Taken together, these results provide initial data into the composition and function of the prostate cancer ncRNA transcriptome.
DISCUSSION
To our knowledge, this study represents the largest RNA-Seq analysis to date and the first to comprehensively analyze a common epithelial cancer from a large cohort of human tissue samples. As such, our study has adapted existing computational tools intended for small-scale use 3 and developed new methods to distill large numbers of transcriptome data sets into a single consensus transcriptome assembly that accurately represents disease biology (Supplementary Discussion) .
Among the numerous uncharacterized ncRNA species detected by our study, we have focused on 121 PCATs, which we believe represent a set of uncharacterized ncRNAs that may have important biological functions in this disease. In this regard, these data contribute to a growing body of literature supporting the importance of unannotated ncRNA species in cellular biology and oncogenesis 6-12 ,
PCAT-1
High PCAT-1 expression
Low PCAT-1 expression A r t i c l e s and broadly our study confirms the utility of RNA-Seq in defining functionally important elements of the genome [2] [3] [4] . Of particular interest is our discovery of the prostate-specific ncRNA gene PCAT-1, which is markedly overexpressed in a subset of prostate cancers, particularly metastases, and may contribute to cell proliferation in these tumors. It is also notable that PCAT-1 resides in the 8q24 'gene desert' locus, in the vicinity of well-studied prostate cancer risk SNPs and the c-MYC oncogene, suggesting that this locusand its frequent amplification in cancer-may be linked to additional aspects of cancer biology (Supplementary Discussion) . In addition, the interplay between PRC2 and PCAT-1 further suggests that this ncRNA may have an important role in prostate cancer progression (Fig. 6e) . Other ncRNAs identified by this analysis may similarly contribute to prostate cancer as well. Furthermore, recent preclinical efforts to detect prostate cancer noninvasively through the collection of patient urine samples have shown promise for several urine-based prostate cancer biomarkers, including the ncRNA PCA3 (refs. 44, 45) . Although additional studies are needed, our identification of ncRNA biomarkers for prostate cancer suggests that urine-based assays for these ncRNAs may also warrant investigation, particularly for those that may stratify patient molecular subtypes.
Our findings support an important role for tissue-specific ncRNAs in prostate cancer and suggest that cancer-specific functions of these ncRNAs may help to drive tumorigenesis. We further speculate that specific ncRNA signatures may occur universally in all disease states and that applying these methodologies to other diseases may reveal key aspects of disease biology and clinically important biomarkers.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/. Accession codes. Data from RNA-Seq experiments are deposited at the NCBI Gene Expression Omnibus as GSE25183. PCAT-1 and PCAT-14 nucleotide sequences are deposited at GenBank nucleotide database (nuccore) as HQ605084 and HQ605085, respectively.
